Takeda/Lilly Actos/Insulin Concomitant Use Represents 23% Of Total Patients
Executive Summary
Concomitant Actos/insulin use represents 23% of total Actos diabetes patients, Takeda said
You may also be interested in...
Avandia/Insulin Safety Warnings Cited In FDA Ad Letters To GSK
GlaxoSmithKline and FDA will discuss an Avandia "Dear Doctor" letter to highlight new safety labeling related to use with insulin following a warning letter issued to the company July 17.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials